| Literature DB >> 31297282 |
Mukhtar Jaderson1, Ju-Hyeong Park2.
Abstract
BACKGROUND: Liquid chromatography-tandem mass spectrometry (LC-MSMS) for simultaneous analysis of multiple microbial secondary metabolites (MSMs) is potentially subject to interference by matrix components.Entities:
Keywords: Dust sample; Mass spectrometry; Matrix effect; Microbial; Secondary metabolite
Year: 2018 PMID: 31297282 PMCID: PMC6598797 DOI: 10.1016/j.shaw.2018.12.004
Source DB: PubMed Journal: Saf Health Work ISSN: 2093-7911
List of MSMs, abbreviations, the suppliers, and CAS numbers
| No. | Analyte | Abbreviation | Supplier | CAS no. |
|---|---|---|---|---|
| 1 | 3-Nitropropionic acid | NITP | Sigma-Aldrich | 504-88-1 |
| 2 | Aflatoxin B1 | AFB1 | Sigma-Aldrich | 1162-65-8 |
| 3 | Aflatoxin B2 | AFB2 | Fermentek | 7220-81-7 |
| 4 | Aflatoxin G1 | AFG1 | Sigma-Aldrich | 1165-39-5 |
| 5 | Aflatoxin G2 | AFG2 | Sigma-Aldrich | 7241-98-7 |
| 6 | Alternariol | ALT | Sigma-Aldrich | 641-38-3 |
| 7 | Alternariol Monomethylether | AME | Adipogen | 26894-49-5 |
| 8 | Asperglaucide | ASPG | ChemFaces | 56121-42-7 |
| 9 | Chaetoglobosin A | CTGA | Adipogen | 50335-03-0 |
| 10 | Citreorosein | CITRO | ChemFaces | 481-73-2 |
| 11 | Citrinin | CIT | Sigma-Aldrich | 518-75-2 |
| 12 | Cyclo(L-Pro-L-Tyr) | CYCLO | Bioaustralis | 4549-02-4 |
| 13 | Deoxynivalenol | DON | Sigma-Aldrich | 51481-10-8 |
| 14 | Diacetoxyscirpenol | DAS | CAYMAN | 2270-40-8 |
| 15 | Emodin | EMOD | Sigma-Aldrich | 518-82-1 |
| 16 | Fumonisin B1 | FUB1 | Sigma-Aldrich | 116355-83-0 |
| 17 | Integracin A | INTA | Santa Cruz | 224186-03-2 |
| 18 | Integracin B | INTB | Santa Cruz | 224186-05-4 |
| 19 | Neoechinulin A | NEOA | ChemFaces | 51551-29-2 |
| 20 | Neosolaniol | NEO | Sigma-Aldrich | 36519-25-2 |
| 21 | Nivalenol | NIV | Fermentek | 23282-20-4 |
| 22 | Ochratoxin A | OTA | Sigma-Aldrich | 303-47-9 |
| 23 | Roquefortine C | ROQC | Santa Cruz | 58735-64-1 |
| 24 | Skyrin | SKY | Sigma-Aldrich | 602-06-2 |
| 25 | Stachybotrylactam | STCH | Santa Cruz | 163391-76-2 |
| 26 | Sterigmatocystin | STEG | Sigma-Aldrich | 10048-13-2 |
| 27 | T-2 toxin | T2 | Fermentek | 21259-20-1 |
| 28 | Valinomycin | VAL | Sigma-Aldrich | 2001-95-8 |
| 29 | Verrucarin A | VERA | Sigma-Aldrich | 3148-09-2 |
| 30 | Verrucarol | VERO | Sigma-Aldrich | 2198-92-7 |
| 31 | Zearalenone | ZEA | Sigma-Aldrich | 17924-92-4 |
MSMs, microbial secondary metabolites.
Sigma-Aldrich, St. Louis, MO, USA; Fermentek, Jerusalem, Israel; Adipogen, San Diego, CA, USA; ChemFaces, Hubei, China; Bioaustralis, Smithfield, NSW, Australia; Cayman, Ann Arbor, MI, USA; Santa Cruz, Dallas, TX, USA.
Precursor and product ions, MSMS conditions, and LC retention time (RT) of all MSMs and ISTD
| Abbreviation | Precursor ion (m/z) | Cone voltage (V) | Product ions (m/z) (1st, 2nd) | Collision energy (V) (1st, 2nd) | RT (min) |
|---|---|---|---|---|---|
| AFB1 | 313.1 [M+H]+ | 62 | 241.1, 284.9 | 40, 24 | 5.4 |
| AFB2 | 315.2 [M+H]+ | 58 | 287.1, 259.1 | 28, 30 | 5.3 |
| AFG1 | 329.1 [M+H]+ | 58 | 243.0, 311.0 | 28, 22 | 5.2 |
| AFG2 | 331.1 [M+H]+ | 60 | 313.0, 245.0 | 26, 32 | 5.0 |
| ALT | 257.0 [M-H]− | 56 | 212.3, 189.0 | 24, 24 | 5.9 |
| AME | 273.2 [M+NH4]+ | 54 | 127.9, 115.0 | 50, 54 | 6.8 |
| ASPG | 445.5 [M+H]+ | 50 | 367.2, 349.2 | 18, 18 | 5.9 |
| CIT | 251.2 [M+H]+ | 28 | 233.0, 191.0 | 18, 26 | 5.6 |
| CITRO | 285.1 [M-H]− | 62 | 224.0, 241.0 | 34, 26 | 6.2 |
| CTGA | 529.5 [M+H]+ | 32 | 130.0, 511.3 | 38, 10 | 6.6 |
| CYCLO | 261.2 [M+H]+ | 36 | 136.0, 154.1 | 18, 28 | 4.3 |
| DAS | 384.3 [M+NH4]+ | 24 | 307.2, 105.0 | 12, 32 | 5.6 |
| DOM | 297.2 [M+H]+ | 28 | 249.1, 203.1 | 10, 16 | 4.4 |
| DON | 281.2 [M+H]+ | 26 | 109, 233.1 | 22, 10 | 4.7 |
| EMOD | 269.0 [M-H]− | 66 | 225.0, 240.9 | 28, 28 | 7.5 |
| FUB1 | 722.6 [M+H]+ | 62 | 352.3, 704.4 | 38, 32 | 5.8 |
| INTA | 629.7 [M+H]+ | 26 | 349.1, 289.2 | 16, 30 | 8.4 |
| INTB | 587.6 [M+H]+ | 24 | 307.2, 167.0 | 14, 26 | 7.9 |
| NEO | 400.3 [M+NH4]+ | 20 | 305.1, 215.1 | 12, 20 | 4.7 |
| NEOA | 324.3 [M+H]+ | 28 | 156.9, 130.0 | 42, 52 | 5.8 |
| NITP | 117.8 [M-H]− | 20 | 45.9 | 6 | 2.1 |
| NIV | 313.2 [M+H]+ | 26 | 205.1, 125.0 | 12, 12 | 4.0 |
| OTA | 404.3 [M+H]+ | 32 | 239.0, 358.1 | 22, 14 | 6.3 |
| ROQC | 390.2 [M+H]+ | 16 | 193.0, 322.1 | 30, 22 | 6.3 |
| SKY | 539.3 [M+H]+ | 68 | 521.1, 504.0 | 30, 46 | 7.7 |
| STCH | 386.4 [M+H]+ | 70 | 178.1, 150.1 | 38, 46 | 7.0 |
| STEG | 325.2 [M+H]+ | 50 | 310.1, 281.0 | 22, 54 | 6.8 |
| T2 | 484.4 [M+NH4]+ | 26 | 305.1, 185.1 | 14, 20 | 6.3 |
| VAL | 1128.7 [M+NH4]+ | 66 | 343.3, 1083.7 | 71, 43 | 9.7 |
| VERA | 520.4 [M+NH4]+ | 24 | 249.1, 457.2 | 18, 14 | 6.2 |
| VERO | 267.1 [M+H]+ | 16 | 249.1, 231.1 | 6, 12 | 4.9 |
| ZEA | 317.1 [M-H]− | 52 | 130.9, 174.9 | 30, 26 | 6.6 |
AFB1, aflatoxin B1; AFB2, aflatoxin B2; AFG1, aflatoxin G1; AFG2, aflatoxin G2; ALT, alternariol; AME, alternariol monomethylether; ASPG, asperglaucide; CIT, citrinin; CITRO, citreorosein; CTGA, chaetoglobosin A; CYCLO, cyclo(L-Pro-L-Tyr); DAS, diacetoxyscirpenol; DOM, deepoxy-deoxynivalenol; DON, deoxynivalenol; EMOD, emodin; FUB1, fumonisin B1; INTA, integracin A; INTB, integracin B; ISTD, internal standard; LC, liquid chromatography; MSMS, tandem mass spectrometry; MSMs, microbial secondary metabolites; NEO, neosolaniol; NEOA, neoechinulin A; NITP, 3-nitropropionic acid; NIV, nivalenol; OTA, ochratoxin A; ROQC, roquefortine C; SKY, skyrin; STCH, stachybotrylactam; STEG, sterigmatocystin; T2, T-2 toxin; VAL, valinomycin; VERA, verrucarin A; VERO, verrucarol; ZEA, zearalenone.
We found only one transition for the MSM.
Fig. 1Percent suppression due to matrix effects of selected sixteen MSMs for Building 1. MSMs, microbial secondary metabolites.
Fig. 2Percent recoveries of selected sixteen MSMs for Building 1 after adjustment using matrix-matched calibration (denoted as A) and internal standard DOM (denoted as B). DOM, deepoxy-deoxynivalenol; MSMs, microbial secondary metabolites.
Fig. 3Extraction efficiencies of selected sixteen MSMs for Building 1. MSMs, microbial secondary metabolites.
Fig. 4Percent coefficient of variations of responses of duplicate injections for selected sixteen MSMs by the spiking type (spiking in neat solvent and spiked in samples before and after extraction) for Building 1. MSMs, microbial secondary metabolites.